SFGP
INTS icon

Stonebridge Financial Group (Pennsylvania)’s Intensity Therapeutics INTS Stock Holding History

Stonebridge Financial Group (Pennsylvania)’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,095
Closed -$31.7K – 272
2025
Q4 		$31.7K Buy
3,095
+920
+42% +$9.33K ﹤0.01% 247
2025
Q3 		$13.2K Buy
2,175
+1,514
+229% +$10.8K ﹤0.01% 239
2025
Q2 		$5.07K Buy
661
+280
+73% +$5.75K ﹤0.01% 235
2025
Q1 		$18.8K Buy
381
+49
+15% +$2.73K ﹤0.01% 506
2024
Q4 		$14.6K Buy
+332
New +$24.1K ﹤0.01% 543

Other funds holding INTS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Stonebridge Financial Group (Pennsylvania)'s INTS Position: Q1 2026 in Review

Stonebridge Financial Group (Pennsylvania) sold out of Intensity Therapeutics (INTS) in Q1 2026, closing a stake of 3,095 shares — an estimated $31.7K sold.

Stonebridge Financial Group (Pennsylvania) first reported a position in INTS in Q4 2024 and held it in 5 quarters. The position peaked at $31.7K in Q4 2025. 13 funds tracked by Wall St. Rank hold INTS as of Q1 2026.

  • Stonebridge Financial Group (Pennsylvania) reported no remaining Intensity Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Stonebridge Financial Group (Pennsylvania) sold 3,095 Intensity Therapeutics shares in Q1 2026, an estimated $31.7K.
  • Stonebridge Financial Group (Pennsylvania) first reported a position in Intensity Therapeutics in Q4 2024 and held it in 5 quarters.
  • Stonebridge Financial Group (Pennsylvania)'s Intensity Therapeutics position peaked at $31.7K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q1 2026.

Based on Stonebridge Financial Group (Pennsylvania)'s 13F filing for Q1 2026, filed 8 Apr 2026.